ClinicalTrials.gg
CompletedNCT05905653Updated Dec 5, 2023

Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers

A Phase 1 interventional study of STN1012600 ophthalmic solution 0.002% in Healthy Adult Males Volunteers, sponsored by Santen Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by Santen Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
Male
01

Study summary

To evaluate the safety and plasma pharmacokinetics of STN1012600 ophthalmic solution 0.002% (1 drop once daily for 7 days) in healthy adult male subjects.

02

Conditions studied

  • Healthy Adult Males Volunteers
03

In context

Lead sponsor

Santen Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who can comply with scheduled visits and the examination and observation as specified in the clinical study protocol

Exclusion criteria

Exclusion Criteria:

  • Subjects have a disease and/or abnormal laboratory value which is considered inappropriate from safety evaluation perspective
  • Subjects who are inappropriate as participants in this study in the opinion of the investigator or sub investigator
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    STN1012600 0.002%

    Drug: STN1012600 ophthalmic solution 0.002%

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration [Cmax]

    Calculate plasma pharmacokinetic parameters and study pharmacokinetics.

    Time frame: 1 week, Day 1 and Day 7

Secondary outcomes

  1. Area Under The Curve From Time Zero to the Last Sampling Time [AUC 0-t]

    Calculate plasma pharmacokinetic parameters and study pharmacokinetics.

    Time frame: 1 week, Day 1 and Day 7

07

Study locations

1 site
  • Medical Corporation Heishinkai OPHAC Hospital
    Osaka, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Jun 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 15, 2023
StartActual
May 25, 2023
Primary completionActual
Jun 21, 2023
CompletionActual
Jun 21, 2023
Last update
Dec 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05905653
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
May 25, 2023
Primary completion
Jun 21, 2023
Completion
Jun 21, 2023
Last update
Dec 5, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sepetaprost

Start the discussion